Tag Archive for: Destiny Pharma

Destiny Pharma plc – Dr Debra Barker Appointed Interim CEO

Brighton, United Kingdom – 25th May 2023: Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces, ahead of the AGM, that Neil Clark has decided to step down as Chief Executive Officer to pursue new challenges. Neil will also step down […]

Destiny Pharma and SporeGen® announce update from research collaboration under Innovate UK grant award to develop a biotherapeutic treatment (SPOR-COV®) for COVID-19 and Influenza

Positive results from testing SPOR-COV in several COVID-19 and influenza research models support potential as prophylactic nasal spray Toxicology studies support safety profile Manufacturing process established Manufacturing and regional licensing agreement signed with HURO Biotech JSC for Vietnam Phase 1 clinical studies completed successfully in Vietnam by HURO Retail product based on SPOR COV technology […]

Destiny Pharma advances strategy against bacteria

Destiny Pharma, one of our longstanding clients, featured in the April 2023 edition of MedNous, the specialist medical research journal. Neil Clark, CEO, and Dr Bill Love, Founder and CSO, sat down with Victoria English to discuss the fantastic progress that has been made with Destiny’s two lead assets, XF-73, a nasal gel for the treatment […]

Destiny Pharma – Audited results for the year ended 31 December 2022

Exclusive North American partnering deal worth up to $570m plus royalties secured for NTCD-M3 Phase 3 development plans finalised for XF-73 nasal following scientific advice from FDA and EMA XF-73 dermal commenced clinically enabling safety study sponsored by US Government’s NIAID New XF research projects initiated in cystic fibrosis and oral mucositis Leadership strengthened with appointment of […]

Destiny Pharma plc – Landmark data published on successful NTCD-M3 gut colonisation after fidaxomicin administration

Brighton, United Kingdom – 4 April 2023 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces that data generated from a C. difficile infection (CDI) model study on the ability of M3 (NTCD-M3), a non-toxigenic C. difficile strain, to successfully colonise the gut following administration […]